Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

9 Mistakes That May Be Hurting Your Sales & Marketing Campaigns

There are many sales prospecting methods that exist nowadays, including email, social media, and cold calling, just to name a few. But are the methods you’re using hurting you more than helping?

Read More »

House speaker says U.S. has ‘plenty of money’ for Zika

U.S. House of Representatives Speaker Paul Ryan said on Tuesday that the federal government has enough funds to deal with the Zika outbreak, without having to resort to funds set aside separately for Ebola in Africa.   “There is plenty of money in the pipeline right now, money that is not going to Ebola, that […]

Read More »

FDA Bans Clinical Trial Coordinator Who Created Fake Patients, Pocketed Money

The U.S. FDA permanently debarred Wesley McQuerry, a former DePaul University clinical trial coordinator, from working on any drug applications.

Read More »

Hillary Clinton Campaign Distances Itself from Embattled Theranos

March 22, 2016 By Alex Keown, Breaking News Staff   PALO ALTO, Calif. – Neither the offices of embattled Theranos, nor the home of Elizabeth Holmes, the company’s chief executive officer, will be the site of a fundraiser for Hillary Clinton, a Democratic presidential candidate, as was previously thought. Holmes is one of 11 […]

Read More »

After Oncology Trial Failures, Investors Urge Gilead to Buy, Buy, Buy

Investors are not completely happy with Gilead Sciences’ share price, which is down about 10 percent from its starting point in 2015.

Read More »

Janssen R&D, Genentech Forge Clinical Trials Agreement

Janssen R&D and Genentech to initiate two studies to determine the safety and tolerability of daratumumab (Darzalex) and atezolizumab for multiple myeloma and solid tumor.

Read More »

36 DMD Experts Send Letter to the FDA Urging Approval of Sarepta’s Drug

March 22, 2016By Mark Terry, Breaking News Staff   Thirty-six experts in Duchenne Muscular Dystrophy (DMD) signed a letter to the U.S. Food and Drug Administration (FDA) urging the regulatory agency to approve eteplirsen, a drug developed by Cambridge, Mass.-based Sarepta Therapeutics (SRPT). Originally the FDA’s Peripheral and Central Nervous System Advisory Committee was […]

Read More »

Evotec Spins off Auto-Immune Disease Company as ‘Topas Therapeutics GmbH’

Topas Therapeutics GmbH is based on a proprietary nanoparticle platform which supports antigen-specific tolerance induction for multiple indications Strong consortium consisting of Epidarex Capital, EMBL Ventures, Gimv and Evotec AG supports strategic Series A financing round of EUR 14 m Initiation of first clinical trials expected in 2017   March 22, 2016 02:24 AM Eastern […]

Read More »

France wants medicine prices to be on agenda at G7 summit: source

French President Francois Hollande wants the issue of medicine prices to be on the agenda at the G-7 summit in Japan in May, a source at the French presidency said on Monday.

Read More »

Fitness trackers bad at keeping tabs on how much energy we burn

Fitness trackers may be a trendy way to monitor every step we take, but these gadgets are actually pretty bad at keeping tabs on how much energy we burn, a new study suggests.

Read More »

BioMarin drug fails to show inattention, mood benefit in study

BioMarin’s genetic disorder drug met the study’s main goal of reducing a toxic buildup of an amino acid, but did not show enough benefit in related inattention and mood complications.

Read More »

Valeant Hunts for New CEO

J. Michael Pearson is out at Valeant Pharmaceuticals and the company is looking for a new chief executive officer.

Read More »

Presidential Contender Asks the U.S. Treasury to Block Pfizer’s Major Tax Evasion

U.S. Sen. Bernie Sanders called on the U.S. Department of the Treasury to block Pfizer plan to relocate overseas as part of its merger with Allergan to cut its tax burden.

Read More »

UK cost agency backs J&J cancer drug in change of heart

A cancer drug originally discovered in Britain has finally been endorsed for treating advanced prostate cancer before chemotherapy on the country’s state health service in a change of heart by the cost agency NICE.

Read More »

WHO suspends TB drugs from big India supplier on quality fears

The World Health Organization has suspended the approval of tuberculosis drugs made by India’s Svizera Labs, a major supplier to developing countries, following an investigation into standards.

Read More »

E-Commerce: Its improvement and foreseeable future views

The e-commerce may possibly be defined being a fashionable small business methodology that addresses the requires of corporations, merchants, and individuals to chop expenditures when enhancing the standard of products and products and rising the velocity of company shipping and delivery, by making use of Internet. The development of digital commerce advanced as the strategy […]

Read More »

J&J psoriasis drug Stelara eases Crohn’s disease in second trial

Johnson & Johnson’s Stelara psoriasis drug has shown effectiveness against Crohn’s disease in a second late-stage trial, bolstering prospects of its approval for the additional use.

Read More »

Brazil says confirmed and suspected microcephaly cases rise to 5,131

The number of confirmed and suspected cases of microcephaly in Brazil associated with the Zika virus has risen to 5,131 from 4,976 a week earlier, the Ministry of Health said on Friday.   Of these, the number of confirmed cases climbed to 863 from 745 a week earlier, while suspected ones increased to 4,268 from […]

Read More »

U.S. FDA rejects Eagle Pharma’s blood thinner

The U.S. Food and Drug Administration rejected Eagle Pharmaceuticals Inc.’s drug to prevent blood clots in certain patients undergoing heart surgery.

Read More »

Helsinn and Eisai Announce Revised U.S. Collaboration for CINV Franchise

Helsinn and Eisai Inc. announced a revised agreement for their chemotherapy-induced nausea and vomiting (CINV) franchise.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom